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Abstract 
Characteristics of specific 125I-to-conotoxin GVIA (125I-to-CgTX) binding and 125I-to-CgTX labeling using bifunctional crosslinkers 
were systematically investigated in crude membranes from chick whole brain. Aminoglycosides and dynorphine A (1-13) inhibited the 
specific binding of 125I-to-CgTX, but not that of the L-type calcium ion channel antagonist [3HI( +)PN200-110. It seems likely that the 
inhibitory effect of dynorphine A (1-13) does not involve r-opiate receptors, based on results with the opiate receptor antagonist 
naloxone and the r-opiate receptor agonist U50488H. Spider venom, Cd 2÷ and La 3+ inhibited the specific binding of 125I-to-CgTX, as 
well as that of [3H](+)PN200-110. Various L-type Ca 2÷ channel antagonists did not affect the specific binding of 125I-to-CgTX. 
125I-oJ-CgTX specifically labeled 135 kDa and 215 kDa bands in crude membranes under reduced and non-reduced conditions, 
respectively. The crosslinker disuccinimidyl suberate (DSS) yielded better 125I-to-CgTX labeling than the other two crosslinkers tested. 
We investigated the effect of various Ca 2+ channel antagonists on 125I-to-CgTX labeling with DSS in detail, and found that there is a 
2+ 125 strong correlation between the effects of Ca channel antagonists on I-to-CgTX labeling of the 135 kDa band and specific 
125I-to-CgTX binding. These results suggest hat aminoglycosides and dynorphine A (1-13) are specific inhibitors of specific 
125I-to-CgTX binding, and that labeling of the 135 kDa band with 125I-to-CgTX using DSS involves the specific binding sites of 
125I-to-CgTX, perhaps including one of the neuronal N-type Ca 2+ channel subunits in the crude membranes. 
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1. Introduction 
Voltage-sensitive calcium channels (VSCCs) are widely 
distributed in excitable cells and play a fundamental role in 
the regulation of many intracellular processes [1-3]. Elec- 
trophysiological nd pharmacological studies on embry- 
onic chick dorsal root ganglion cells in culture have re- 
vealed the presence of three types of VSCCs in neuronal 
tissue: i.e., L-, N-, and T-type VSCCs [4]. These three 
types of VSCCs have different electrophysiological and 
pharmacological characteristics. It has recently become 
apparent that there is a fourth type of Ca 2+ channel, a 
P-type channel, present in some neurons (mainly in cere- 
bellar Purkinje cells) [5,6]. 
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to-Conotoxin GVIA (to-CgTX), which is isolated from 
the venom of a marine snail, Conus geographus [7], specif- 
ically blocks calcium currents through neuron-specific 
VSCCs [8-12]. This toxin appears to act on neuronal 
N-type VSCCs [9,11,13]. Irreversible and specific binding 
of 125I-w-CgTX to chick and rat brain membranes has also 
been investigated [14-16], and the specific binding of 
125I-to-conotoxin to these brain membranes i affected by 
aminoglycoside antibiotics, spider venom of Plectreurys 
tristes and dynorphine A (1-13) [16-18]. However, there 
has been little systematic investigation of the specific 
inhibitory effects of these blockers on 125I-to-CgTX bind- 
ing to N-type VSCCs. 
The molecular masses of the to-CgTX binding sites 
have been determined tobe 310 kDa + 230 kDa + 34 kDa 
[19], 222 kDa [20] and 210 kDa [21] by photoaffinity 
labeling in rat brain membranes, and 135 kDa [22] and 170 
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kDa/140 kDa + 30 kDa [21] by chemical crosslinking in 
chick brain membranes. We have also observed that bands 
of 135 kDa (reduced conditions) and 215 kDa (non-re- 
duced conditions) are selectively labeled with 125I-to-CgTX 
using the crosslinker disuccinimidyl suberate (DSS) in 
chick whole brain, but not in rat whole brain [16]. How- 
ever, there has been little systematic nvestigation of the 
characteristics of 125I-to-CgTX labeling of its binding sites 
in chick whole brain using a crosslinker. 
We used well known Ca 2÷ channel agonist (Ca 2÷ 
agonist) and Ca 2÷ channel antagonists (Ca 2÷ antagonist) 
to identify a specific inhibitor of the specific 125I-to-CgTX 
binding to crude membranes from chick whole brain, and 
we investigated the characteristics of ~25I-to-CgTX labeling 
in the crude membranes using a crosslinker, and particu- 
larly examined whether there is a correlation between the 
effects of various Ca 2÷ antagonists on such labeling and 
the effects of these Ca 2÷ antagonists on the specific 
binding of 125I-to-CgTX. 
2. Materials and methods 
2.1. Preparation of crude membranes 
Crude membranes were prepared from cardiac, ileal, 
and skeletal muscle, and whole brain of 5-day-old chicks 
as described previously [16,23,24]. The concentrations of 
protein in these crude membrane preparations were 4.42 ___ 
0.20 (n = 5), 5.30 + 0.78 (n = 5), 5.16 + 0.62 (n = 5) and 
6.20 + 0.62 (n = 5) mg protein/ml, respectively. 
2.2. Assay of 125I-to-CgTX binding 
Specific binding of 125I-to-CgTX to the various types of 
crude membranes was assayed by a modification of the 
methods of Abe et al. [14], Cruz and Olivera [15] and 
Ichida et al. [16]. 
50-/zl aliquots of the crude membranes (about 75 
/xg/tube; the concentrations of these crude membranes 
were adjusted to 1.5 mg protein/ml) were added to assay 
medium consisting of 50 mM 4-(2-hydroxyethyl)-l- 
piperazineethanesulfonic acid (Hepes)-tris(hydroxy- 
methyl)aminomethane (Tris) (pH 7.4 at 4°C), 0.1% bovine 
serum albumin (BSA), and various concentrations of 125I- 
to-CgTX with or without unlabeled to-CgTX at 1000-fold 
the concentration of 125I-to-CgTX. The concentration of
100 pM 125I-to-CgTX in the absence and presence of 100 
nM unlabeled to-CgTX was used in the examination of the 
effects of Ca 2 + agonist and antagonists. The final volume 
of the assay system was 200 /~1. After incubation for 14 h 
at 4°C, the mixture was rapidly filtered through a What- 
man GF/C glass filter that had been preimmersed in 
ice-cold washing solution with suction and the filter was 
washed four times with 2 ml of ice-cold washing solution 
consisting of 50 mM Hepes-Tris (pH 7.4 at 4°C), 0.1% 
BSA, 1.5 mM CaC12, and 160 mM choline chloride. The 
radioactivity on the filter was counted in a "y-counter 
(Aloka, JDC-752). 
The specific binding of [3H](+)PN200-110 
([3H](+)PN) to crude membranes from rat whole brain 
was assayed by a modification of a previously reported 
method [23]. 50-/zl aliquots of the crude membranes (about 
80 /xg/tube; 1.6 mg protein/ml) were added to assay 
medium consisting of 50 mM Tris-HC1 (pH 7.4 at 30°C), 
0.5 mM phenylmethylsulfonyl fluoride, 0.15 M NaCI, 1 
mM CaCI 2, and 0.25 nM [3H](+)PN in the absence and 
presence of unlabeled 0.25 /zM (+)PN. The final volume 
of the assay mixture was 450 ~1. After incubation for 50 
min at 30°C, the mixture was rapidly filtered through a 
Whatman GF/C glass filter with suction and the filter was 
washed four times with 4 ml of ice-cold 50 mM Tris-HCl 
buffer (pH 7.4 at 30°C). The filter was then transferred toa 
counting vial, 5 ml of Triton/toluene-based scintillation 
mixture was added, and the radioactivity was counted in a 
liquid scintillation counter (Packard Tricarb 2050). 
Binding studies were carried out in duplicate. All assays 
using derivatives of 1,4-dihydropyridine (DHP) were per- 
formed under a safety light. The specific bindings of 
125I-to-CgTX and [3H](+)PN were defined as the differ- 
ences between the radioactivities bound in the absence 
(total binding) and presence (nonspecific binding) of unla- 
beled to-CgTX and unlabeled (+)PN at 1000-fold the 
concentration of 125I-og-CgTX and [3H](+)PN, respec- 
tively. The results of binding assays were analyzed by 
nonlinear least-squares regression using a computer pro- 
gram (SIMPLEX) [25] from the program library of the Com- 
puter Center, Osaka University. 
2.3. Reaction for crosslinking followed by specific 125I-o)- 
CgTX binding 
Specific binding of 125I-to-CgTX was assayed as de- 
scribed in Section 2.2 with the following modification. 
80-/zl aliquots of the crude membranes (about 300 /xg 
protein/tube; the concentrations of these crude membranes 
were adjusted to about 3.75 mg protein/ml) were added to 
assay medium consisting of 30 mM Hepes-NaOH (pH 7.4 
at 4°C), 0.1% BSA, and 0.1 nM 125I-~CgTX with or 
without unlabeled 0.1 /xM to-CgTX, unless otherwise 
indicated. The final volume of the assay system was 200 
/zl. 
After specific binding of 125I-to-CgTX to the crude 
membranes was carded out for 14 h at 4°C, crosslinking of 
125I-to-CgTX with DSS, disuccinimidyl tartrate (DST) or 
ethylene glycol bis(succinimidyl succinate) (EGS) to its 
binding sites was assayed by a modification of the meth- 
ods of Barhanin et al. [21] and Ichida et al. [16]. The 
reaction mixture for specific 125I-to-CgTX binding was 
centrifuged at 40000 × g for 20 min. The pellets were 
gently washed with 30 mM Hepes-NaOH (pH 8.5 at 22°C) 
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Fig. 1. Effects of aminogtycosides on pecific binding of 12sI-to-CgTX 
(--) and [3H](+)PN(- -). Symbols (O) Ami, (O) Kan, (A) Gen, 
(zx) Str, (•)  Tob, ([3) Neo. Points represent the means of four or 
five preparations from separate animals. Bars indicate standard errors. 
* P < 0.01 as compared with specific [3H](+)PN binding with an equal 
concentration f each aminoglycoside. 
solution and then suspended with the same solution. The 
reaction for crosslinking was initiated by addition of the 
crosslinker DSS (500 /~M). The reaction was stopped by 
addition of 1.2 ml of 100 mM Tris-Cl (pH 8.5 at 22°C) 
after incubation for 1.5 min at 22°C, unless otherwise 
indicated, and centrifuged at 40 000 × g for 20 min. The 
pellets were gently washed once with 100 mM Tris-C1 (pH 
8.5 at 22°C) and then solubilized with Laemmli's ample 
buffer [26] for 30 min at room temperature. The samples 
(about 100 /zg of protein) were then applied to a 5-16% 
gradient gel and submitted to sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE) [26]. For 
SDS-PAGE under non-reduced conditions, 20 mM N- 
ethylmaleimide was used in the sample buffer [26] instead 
of 2% 2-mercaptoethanol. After electrophoresis, the slab 
gel was dried and then exposed with Du Pont Cronex 
Lightning Plus Screens to preflashed Kodak XAR-5 film 
for about 5 days at -75°C. 
2.4. Other methods 
Protein was measured by the method of Lowry et al. 
[27] with BSA as a standard. 
Statistical analyses were performed using the paired or 
unpaired Student's t-test and the statistical evaluation of 
multiple groups was performed by a one-way analysis of 
variance. A P-value of less than 0.05 was chosen as 
statistically significant. 
2.5. Materials 
125I-to-CgTX (to-conotoxin GVIA labeled with 125I in 
Tyr 22, 81.4 TBq/mmol) and ( +)[5-methyl-aH]PN200 - 
110 (2.59-3.22 TBq/mmol)  were purchased from Amer- 
sham or New England Nuclear. EGS, DSS and DST were 
purchased from Pierce (Rockford, IL). Dynorphine (1-13) 
and to-CgTX were purchased from the Peptide Institute 
(Osaka, Japan). Spider venom from Plectreurys tristes 
was purchased from Spider Pharmaceutical (Arizona). 
Amikacin (Ami), gentamycin (Gen), kanamycin (Kan), 
neomycin (Neo), streptomycin (Str) and tobramycin (Tob) 
were purchased from Sigma (St. Louis, MO), Nakarai 
(Kyoto, Japan) or Wako (Osaka, Japan). Naloxone was 
purchased from Sigma (St. Louis, MO). Bay K 8644 was a 
gift from Bayer AG (Leverkusen, Germany), D- and L-di- 
ltiazem was from Tanabe Seiyaku (Osaka, Japan), ni- 
trendipine was from Yoshitomi Pharmaceutical (Osaka, 
Japan), (+)  and ( - )PN 200-110 was from Sandoz (Basel, 
Switzerland), U50488H was from Dr. A. Kawabata (Kinki 
University) and verapamil was from Eisai (Tokyo, Japan). 
1,4-Dihydropyridine (DHP) derivatives and to-CgTX were 
dissolved in 50% PEG#200 and 0.1% BSA, respectively. 
All assays using DHP derivatives were performed under a 
safety light. 
3. Results 
3.1. Specific binding of t25I-w-CgTX and [3H1( + )PN 
Specific binding of 125I-to-CgTX to crude membranes 
from chick whole brain was saturable and irreversible 
(data not shown). A Scatchard plot of the saturation of 
specific 125I-to-CgTX binding gave a single linear curve 
(data not shown). The concentrations for half-maximal 
saturation of the specific binding of lZSI-to-CgTX, values 
of K d and Bma x from the Scatchard plots, and the Hill 
coefficient are shown in Table 1. A concentration of 100 
pM 125I-to-CgTX, which was similar to the K d value from 
the Scatchard plot, was used in all subsequent experiments 
on the specific binding of 125I-to-CgTX to crude mem- 
branes from whole brain. The corrected free concentration 
of 125I-to-CgTX was calculated to be 33.0 + 2.2 pM with 
74.7 _ 3.8 ~g protein of the crude membranes/tube (n = 
12). The specific binding of 125I-to-CgTX at a concentra- 
tion of 100 pM to the crude membranes was 85-90% of 
the total binding. 
Table 1 
Values of K d and Bma x for specific binding of 125I-to-CgTX and [3H](+)PN from Scatchard plots or saturation curves 
Specific binding Concn. for half-maximal Amount of125I-to-CgTX K d value (pM) Bma x
saturation (pM) bound at equilibrium (fmol/mg protein) 
(fmol/mg protein) 
a25I-to-CgTX 87.3 _+ 3.7 948.0 + 29.5 101.2 _ 3.2 1024.1 _+ 53,2 
[3HI( + )PN 2076.7 + 54.5 2310.8 _+ 64.3 2584.9 -F 87.2 2537.0 _+ 76.1 
Hill coefficient 
1.03 _+ 0.04 
0,99 + 0.02 
Values are means :1: S.E. for 4-6 separate animals. 
60 S. Ichida et al. /Biochimica et Biophysica Acta 1233 (1995) 57-67 
On the other hand, specific binding of [3H](+)PN to 
crude membranes from chick whole brain was saturable 
and reversible (data not shown). A Scatchard plot of the 
saturation of specific [3H](+)PN binding gave a single 
linear curve (data not shown). The concentration for half- 
maximal saturation of the specific binding of [3H]( + )PN, 
values of K d and Bma x from the Scatchard plots, and the 
Hill coefficient are shown in Table 1. Although the K d 
value for specific [3H](+)PN binding was 2.59 nM (from 
the Scatchard plot), as shown in Table 1, a concentration 
of 0.25 nM (250 pM) [3H](+)PN was used in all subse- 
quent studies of the effects of Ca 2 + antagonists, ince we 
wished to compare these effects with those of various 
Ca 2÷ antagonists on the specific binding of 100 pM 
125 I-to-CgTX. 
3.2. Effects of  Ca 2 + agonist and antagonists 
The effects of aminoglycoside antibiotics which block 
N-type Ca 2+ channels [17], on the specific binding of 
z25I-to-CgTX to crude membranes from chick whole brain 
are shown in Fig. 1. Aminoglycosides including amikacin 
(Ami), gentamycin (Gen), kanamycin (Kan), neomycin 
(Neo), streptomycin (Str) and tobramycin (Tob), inhibited 
the specific binding of 125I-to-CgTX in a dose-dependent 
manner. Their ICs0 values were 9.21 • 10 -5 M, 5.18 • 10 -5 
M, 1.18.10 -4 M, 5.62.10 -5 M, 1.28.10 -4 M and 
4.77.10 -5 M, respectively. However, these aminoglyco- 
sides had little effect on the specific binding of 0.25 nM 
[3H]( +)PN. These results suggest hat these aminoglyco- 
sides specifically inhibited the specific binding of 125I-to- 
CgTX to the crude membranes. 
to-CgTX, dynorphine A (1-13) and spider venom from 
Plectreurys tristes inhibited the specific binding of 125I-to- 
CgTX to the crude membranes. Their ICs0 values were 
7 .10  -1° M, 3 .10  -5 M and 1 • 10 -5 g/ml, respectively 
(Fig. 2A-C). However, only the spider venom had a 
marked effect on the specific binding of 0.25 nM 
[3H](+)PN (Fig. 2C). The ICs0 value of spider venom for 
the specific binding of 12sI-m-CgTX was similar to that for 
the specific binding of [3H](+)PN. These results suggest 
that to-CgTX and dynorphine A (1-13) specifically inhib- 
ited the specific binding of 125I-to-CgZX to the crude 
membranes, but spider venom did not. 
To investigate the possibility that the inhibitory effect 
of dynorphine A (1-13) on the specific binding of 125I-w- 
CgTX to the crude membranes i due to participation of 
r-opiate receptors, the effects of US0488H (a r-opiate 
receptor agonist) and naloxone (a /x-, r- and &opiate 
receptor antagonist) on the specific binding of 125 I-to-CgTX 
to the crude membranes were examined (Fig. 3). Neither 
naloxone (1 /xM) nor U50488H (1 ~M and 30 /xM) 
affected the specific binding. Furthermore, 1 p,M naloxone 
did not alter the inhibitory effect of 100/zM dynorphine A 
(1-13) on the specific binding. These results suggest hat 
the inhibitory effect of dynorphine A (1-13) on the 
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Fig. 2. Effects of to-CgTX (A), dynorphine A (1-13) (B) and spider 
venom (C) on specific binding of t2sI-to-CgTX (0) and [3H]( +)PN (O). 
Points represent the means of 4 to 10 preparations from separate animals. 
Bars indicate standard errors. *P < 0.01 as compared with the specific 
[3H]( + )PN binding with an equal concentration of to-CgTX (A), dynor- 
phine A (1-13) (B) or spider venom (C). 
specific binding of 125I-o)-CgTX to crude membranes i
not due to an opiate-related mechanism involving r-opiate 
receptors. 
Inorganic alcium antagonists, Cd 2÷ and La 3+ , inhib- 
ited the specific binding of 125I-to-CgTX to the crude 
membranes (Fig. 4A and B). The IC50 values for Cd 2+ 
and La 3+ were 4.8.10 -4 and 2.5.10 -4 M, respectively. 
However, the specific binding of [3H](+)PN was also 
inhibited by Cd 2+ and La 3+ . In this case, the respective 
ICso values were 1.2.10 -4 M and 4.0.10 -4 M, and 
Cd 2+ and La 3 + inhibited [3HI( +)PN binding and 125I-to- 
CgTX binding similarly. 
Various Ca 2+ antagonists and agonist, such as D-diltia- 
zem, L-diltiazem, nitrendipine, (+)PN, ( - )PN,  verapamil, 
and Bay K 8644, at concentrations ranging from 1 • 10 -7 
to 3 • 10 -4 M did not affect he specific binding of tESI-to- 
CgTX to the crude membranes (data not shown). 
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Fig. 5 shows the specific binding of 125I-to-CgZX to 
crude membranes from various chick organs, including 
whole brain, and cardiac, ileal, and skeletal muscle. 125I- 
to-CgTX was observed to specifically bind to crude mem- 
branes from whole brain, but not to crude membranes from 
the other organs. These results suggest that the specific 
binding sites of lzsI-to-CgTX exist mainly in whole brain. 
3.3. Characteristics of labeling with crosslinkers 
Fig. 6A shows the specific labeling of 0.1 nM 1251-og- 
CgTX with the bifunctional reagents (500/xM) DSS, DST 
and EGS in crude membranes from chick whole brain. 
125I-to-CgTX specifically labeled its binding sites in the 
crude membranes with DSS and EGS. The reaction time 
for crosslinking by the crosslinkers was 1.5 min at 4°C. 
The apparent molecular masses of the labeled sites using 
DSS or EGS under reduced and non-reduced conditions 
were 135.0 __+ 1.6 (n = 12) kDa and 215.3 _ 3.3 (n = 15) 
kDa, respectively. The specific l~sI-to-CgTX labeling of 
the 135 kDa and 215 kDa bands by DSS was stronger than 
that by EGS. DST did not provide specific labeling of the 
135 kDa and 215 kDa bands under reduced or non-reduced 
conditions. Therefore, the crosslinker DSS was used in all 
subsequent experiments for l~sI-to-CgTX labeling of its 
binding sites on the crude membranes. When the cross- 
linking reaction was carried out in the absence of 
crosslinker, labeling was not observed despite the use of 
different conditions, such as the absence or presence of 
unlabeled to-CgTX and SDS-PAGE under reduced or 
non-reduced conditions. On the other hand, when the 
SDS-PAGE gels that had been prepared under various 
conditions were stained with Coomassie brilliant blue 
"O 
u"a 
o. u~ 
A 
,oo- 
O- I , , 
5 4 3 
-10g [ Cd 2+ ] (M) 
- I00 
- 50  
, 0 
2 
I 
zo  
I 
A~ 
v 
B 
lO0 - 1 O0 
I 
"~o  
÷ 
u 
"~, ~ ¢\0  ~ 0 
~O--  a~ 
0 , , ~ 0 
- log [ La 3+ ] (M) 
Fig. 4. Effects of Cd 2+ (k) and La 3+ (B) on specific binding of 
12Sl-to-CgTX (O) and [3H](+)PN (O). Points represent the means of 4 
to 6 preparations from separate animals. Bars indicate standard errors. 
(CBB), the patterns were identical (Fig. 6B), suggesting 
that the labeling of the 135 kDa or 215 kDa band with 
12sI-to-CgTX using DSS was not due to an increase in the 
aggregation of the protein in the 135 kDa or 215 kDa 
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Fig. 3. Effects of dynorphine A (1-13), U50488H and naloxone on 
specific binding of 125I-to-CgTX. Columns represent the means of four or 
five preparations from separate animals. Bars indicate standard errors. 
* P < 0.01 as compared with control. 
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Fig. 5. Specific 125I-to-CgTX binding to various crude membranes from 
chick cardiac, ileal, and skeletal muscle and whole brain. Columns 
represent the means of four preparations for separate animals. Bars 
indicate standard errors. *P < 0.005 as compared with the specific 
~2sI-to-CgTX binding in whole brain. 
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Fig. 6. Autoradiographic (A) and CBB-stained (B) patterns of lz~I-to-CgTX labeling with the cross linkers DSS, DST and EGS under reduced and 
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absence and presence of unlabeled ta-CgTX, at 1000-fold the concentration of 125I-to-CgTX, on the reaction medium, respectively. The arrow heads in 
panels A and B indicate the 135 and 215 kDa bands, respectively. 
band. SDS-PAGE was carried out under reduced condi- 
tions in all subsequent experiments, unless otherwise indi- 
cated. 
The crosslinking reaction with DSS showed time (12 
s-15 min)- and dose (62.5-1000 /xM)-dependence (data 
not shown). Based on the results of the preliminary experi- 
ments, a reaction time of 1.5 min and a concentration of
500 /zM were used for the crosslinking with DSS, unless 
otherwise indicated. 
The labeling depended on the initial concentration of
125I-to-CgTX (0.025-0.4 nM), as shown in Fig. 7. The 
extent of labeling of the 135 kDa band gradually increased 
as the concentration of 125I-to-CgTX increased. A 125I-to- 
CgTX concentration f 0.1 nM resulted in the best label- 
ing, since non-specific labeling, which reduced the differ- 
ence between total and non-specific radioactivity in the 
125 135 kDa band, was greatest at I-to-CgTX concentrations 
of > 0.2 nM. Accordingly, a 125I-to-CgTX concentration 
of 0.1 nM was used for labeling in all subsequent experi- 
ments, unless otherwise indicated. 
125I-to-CgTX labeling of the 135 kDa band also de- 
pended on the incubation time in the t25I-to-CgTX binding 
reaction (Fig. 8). Although labeling had apparently reached 
a steady-state at an incubation time of 8 h, an incubation 
time of 14 h was used for labeling in all subsequent 
experiments, unless otherwise indicated, to ensure that a 
steady state had, in fact, been reached. 
The results in Figs. 7 and 8 were consistent with those 
for the dose- and time-dependence of the specific binding 
(data not shown) of 125I-to-CgTX to the crude membranes. 
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Fig. 7. Autoradiographic patterns of ~I-to-CgTX labeling with DSS as a 
function of the concentration of 125I-to-CgTX (0.025-0.4 nM). The 
symbols ( - )  and (+)  indicate the absence and presence of unlabeled 
to-CgTX, at 1000-fold the concentration f 12sI-w-CgTX, on the reaction 
medium, respectively. The arrow heads indicate the 135 kDa band. 
the presence of unlabeled to-CgTX. These results are 
consistent with the inhibitory effects of these Ca 2 ÷ antago- 
nists on the specific binding of 125I-o.,-CgTX and 
[3H](+)PN to crude membranes as shown in Figs. 1, 2 
and 4: i.e., 100 /~M of each of the aminoglycosides, 10 
nM to-CgTX and 100 /xM dynorphine A (1-13) inhibited 
the specific binding of 125I-o~CgTX, but not that of 
[3H](+)PN. On the other hand, 3 mM Cd 2÷, 3 mM La 3÷ 
and 50 $tg/ml spider venom inhibited the specific binding 
of both 12sI-w-CgTX and [3H](+)PN. 
The effects of Ca 2+ agonist and various Ca 2÷ antago- 
nists for L-type VSCCs, such as the DHP derivatives, Dil, 
Reduced 
Fig. 6 (continued). 
Non-reduced 
3.4. Effects of various reagents on labeling 
We investigated the effects of various Ca 2 + antagonists, 
such as aminoglycoside antibiotics (Ami, Gen, Kan, Neo, 
Str. and Tob), to-CgTX, Cd 2÷ , La 3+ , dynorphine A 
(1-13) and spider venom (Fig. 9A), on the 125I-to-CgTX 
labeling of the 135 kDa band in crude membranes from 
chick whole brain. 100 tzM of each of the aminoglyco- 
sides, 10 nM to-CgTX and 100 /xM dynorphine A (1-13) 
specifically inhibited labeling of the 135 kDa band, and 
did not inhibit either the labeling of other bands in the 
absence of unlabeled o,,-CgTX or non-specific labeling in 
the presence of unlabeled to-CgTX. On the other hand, 3 
mM Cd 2+ , 3 mM La 3+ , and 50 /zg/ml spider venom 
inhibited not only the specific labeling of the 135 kDa 
band, but also both the labeling of other bands in the 
absence of unlabeled to-CgTX and non-specific labeling in 
180 
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Fig. 8. Autoradiographic patterns of 12sI-a~-CgliK labeling with DSS as a 
function of time (1-22 h) in a 125I-to-CgTX specific-binding reaction. 
The symbols ( - )  and ( + ) indicate the absence and presence ofunlabeled 
to-CgTX, at 1000-fold the concentration of 125I-w-CgTX, on the reaction 
medium, respectively. The arrow heads indicate the 135 kDa band. 
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Bay, Nit, (+)PN, ( - )PN and Ver, were investigated (Fig. 
9B). Bay, Nit, ( +)PN and ( - )PN at concentrations of 100 
/zM slightly increased labeling of the 135 kDa band, but 
D-Dil, L-Dil and Ver (100 gM) had no effect. These 
results were also consistent with the effects of Ca 2÷ 
agonist and antagonists on the specific binding of 1251-to- 
CgTX to crude membranes (data not shown). 
Fig. 10 shows 125I-to-CgTX labeling of the 135 kDa 
band in crude membranes from various chick organs, 
including whole brain, and cardiac, ileal and skeletal mus- 
cle. Specific labeling was only observed in crude mem- 
branes from chick whole brain, although non-specific la- 
beling was observed in the crude membranes from cardiac 
and skeletal muscle. In this study, we used a standard 
concentration of protein for the crude membranes from the 
different organs in SDS-PAGE (about 330 /xg 
protein/lane). This result was also consistent with the 
specific binding'of 12sI-to-CgTX to these crude membranes 
as shown in Fig. 5. 
All of these results regarding 12sI-to-CgTX labeling of 
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Fig. 9. Effects of various aminoglycoside antibiotics, Cd 2+, to-CgTX, La 3+, dynorphine A (1-13) and spider venom (panel A), and various DHP 
derivatives, D-diltiazem, L-diltiazem and verapamil (panel B) on 12sI-ta-CgTX labeling of the 135 kDa band. The symbols ( - )  and (+) indicate the 
absence and presence of unlabeled to-CgTX, at 1000-fold the concentration f 12sI-to-CgTX, on the reaction medium, respectively. The arrow heads 
indicate the 135 kDa band. 
S. Ichida et al. / Biochimica et Biophysica Acta 1233 (1995) 57-67 65 
the 135 kDa band with DSS were similar to those on the 
specific binding of 125I-a~-CgTX, which suggests that 1251- 
co-CgTX labeling of the 135 kDa band may involve spe- 
cific binding sites of 12sI-a~-CgTX in crude membranes 
from chick whole brain. 
4. Discussion 
4.1. Characteristics of specific 125I-to-CgTX binding 
K d and Bma x values for specific binding of 125I-to-CgTX 
to crude membranes from chick whole brain were compa- 
rable to those reported by other authors [14-16,18,20,21]. 
125I-og-CgTX was observed to specifically bind to crude 
membranes from chick whole brain, but not to crude 
membranes from other organs, suggesting that the specific 
binding sites of 125I-o~-CgTX exist only in whole brain, 
and that these binding sites are N-type VSCCs. Therefore, 
the characteristics of the specific binding sites in crude 
membranes from chick whole brain appear to be similar to 
those reported by other authors [14-16,18,20-22]. 
To identify a selective antagonist of 125I-oJ-CgTX bind- 
ing sites in crude membranes from chick whole brain, 
various types of reagents were investigated with regard to 
specific binding of both 125I-oJ-CgTX and [3H](+)PN. 
Aminoglycoside antibiotics, uch as Ami, Gen, Kan, Neo, 
Str, and Tob (which block N-type VSCCs [17]) and dynor- 
phine A (1-13) (which blocks neuronal Ca 2+ channels 
[28-30]) inhibited the specific binding of 125I-co-CgTX, 
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Fig. 10. Autoradiographic patterns of 125I-¢o-CgTX labeling with DSS of crude membranes from brain, cardiac muscle, ileal muscle and skeletal muscle. 
Two samples from each type of membrane are shown. The concentration of protein for each crude membrane applied in SDS-PAGE was almost the same 
(about 120 /xg protein/lane). The symbols ( - ) and ( + ) indicate the absence and the presence of unlabeled co-CgTX, at 1000-fold the concentration of 
125I-o~CgTX, on the reaction medium, respectively. The arrow heads indicate the 135 kDa band. 
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but not that of [3H](+)PN. On the other hand, crude 
spider venom from Plectreurys tristes (which interferes 
with transmitter release by inhibiting presynaptic Ca 2+ 
entry [31]) and inorganic divalent cations (Cd 2÷ and 
La 3+ ) inhibited the specific bindings of both 125I-to-CgTX 
and [3H](+)PN with equal potency. These results uggest 
that aminoglycosides and dynorphine A (1-13) specifi- 
cally block specific 125I-to-CgTX binding, but spider 
venom, Cd 2÷ and La 3+ do not. The effects of aminoglyco- 
sides were comparable to those reported by Knaus et al. 
[17] using guinea pig cerebral cortex membranes. 
Feigenbaum etal. [18] have reported that dynorphine A 
(1-13) stimulates 125I-to-CgTX binding to synaptic mem- 
branes from rat brain by increasing toxin affinity through a
non-opiate allosteric mechanism. The stimulating effect of 
dynorphine A (1-13), as reported by Feigenbaum et al. 
[18] contrasts with the results of the present study and with 
those of a previous tudy using crude membranes from rat 
whole brain [16]. However, the cause of this difference in 
the observed effects of dynorphine A (1-13) is unknown. 
In our experiment, the opiate-receptor antagonist naloxone 
(1 /xM) and the r-receptor agonist U50488H (1 and 30 
/zM) did not affect the specific binding of 125I-to-CgTX 
(Fig. 3). Therefore, it seems likely that the inhibitory effect 
of dynorphine A (1-13) is not due to an opiate-related 
mechanism involving x-opiate receptors. Our findings re- 
garding the inhibitory effect of dynorphine A (1-13) were 
comparable with those from electrophysiological experi- 
ments in which dynorphine A blocked neuronal Ca 2÷ 
channels [28-30]. 
Various types of Ca 2+ agonist and antagonists, uch as 
Bay K 8644, D-diltiazem, L-diltiazem, nitrendipine, ( + )PN, 
( - )PN and verapamil, had no effect on the specific bind- 
ing of l~sI-to-CgTX (data not shown). These results were 
generally comparable with those reported by other labora- 
tories [14-16,21], however, the IC50 value for crude spider 
venom on specific binding differed from that reported by 
Feigenbaum et al. [18]. 
To clarify the selective ffect of aminoglycosides and 
dynorphine A (1-13) on the specific binding sites of 
~25I-to-CgTX in chick whole brain, we must further inves- 
tigate the effect of these agents on Ca 2÷ influx via N-type 
VSCCs in chick brain. 
4.2. Labeling of  125I-to-CgTX with crosslinker 
We found that 125I-to-fgTX specifically labeled its 
binding site in crude membranes from chick whole brain 
with DSS under conditions imilar to those in which the 
specific binding of 125I-to-CgTX to the crude membranes 
occurred. The apparent molecular mass of the labeled site 
by SDS-PAGE under reduced and non-reduced conditions 
was 135 kDa and 215 kDa, respectively. The results were 
in part similar to those published by Cruz et al. [22] and 
Barhanin et al. [21]. The results by Barhanin et al. [21], in 
which autoradiography b  SDS-PAGE under reduced and 
non-reduced conditions howed labeling of 140 and 170 
kDa bands in chick brain, respectively, were particularly 
comparable with those in the present study. 
The results of the present study showed that the extent 
of 125I-to-CgTX labeling of its binding site in the crude 
membranes depended on the bifunctional cross-linker used: 
i.e., DSS, DST or EGS (Fig. 6). These reagents differ only 
in the length of the active portion of the bifunctional 
molecule in the crosslinker: the lengths for DSS, DST and 
o 
EGS are 11.4, 6.4 and 16.1 A, respectively. The rank order 
of specific labeling of both the 135 and 215 kDa bands 
was DST <<< EGS < DSS. Therefore, these results sug- 
gested that DSS was the best crosslinker for 125I-to-CgTX 
labeling of the 135 and 215 kDa bands in the crude 
membranes under our experimental conditions. 
On the other hand, labeling with 12sI-to-CgTX using 
DSS in rat brain has not yet been observed [16,21], 
although photoaffinity labeling with azido-derivatives of 
125I-to-CgTX of the 310 kDa + 230 kDa + 34 kDa, 210 
kDa + 36 kDa and 222 kDa bands in rat brain has been 
reported by Abe and Saitsu [19], Barhanin et al. [21] and 
Marqueze t al. [20], respectively. The cause of this differ- 
ence in labeling using DSS between rat and chick brain is 
not yet clear. However, it seems likely that this difference 
is due to the amount of specific 125I-to-CgTX binding in rat 
and chick brain, since the amount of specific binding in 
chick brain is about 5-times greater than that in rat brain 
[16,21]. 
Biochemical studies have shown that DHP-sensitive 
Ca 2+ channels from skeletal muscle T-tubule membranes 
(L-type VSCCs) consist of four distinct subunits, ax (170 
kDa), a2/8  (175 kDa), /3 (52 kDa), and y (32 kDa) 
[32,33]. The 6-subunit can be released from the a2/6-pro- 
tein upon reduction of the disulfide bonds [32,33]. In the 
present study, we showed that while the 215 kDa band was 
labeled under non-reduced conditions, the 135 kDa band 
was labeled under reduced conditions. Therefore, we be- 
lieve that the sites at which the 135 kDa/215 kDa bands 
are labeled under educed/non-reduced onditions in crude 
membranes from chick brain are closely related to the 
characteristics of the a 2 subunit in skeletal L-type VSCCs 
or neuronal VSCCs, although the a 1 subunit is believed to 
provide the binding sites for Ca 2÷ antagonists, DHPs and 
phenylalkylamines [34,35]. 
We investigated the effects of various Ca 2 + agonist and 
antagonists on labeling with 125I-w-CgTX using DSS. A 
correlation was observed between the effects on labeling 
and the effects on the specific binding of 125I-to-CgTX. 
Common findings between the two studies are as follows: 
(a) Time and dose of 125I-to-CgTX dependence were 
observed in both studies, and both the pattern of the 
time-course and the EDs0 value for ~25I-oJ-CgTX labeling 
were similar to those for the specific binding of 12sI-to- 
CgTX (Figs. 7 and 8, and Table 1). 
(b) Labeling of the 135 kDa band was selectively 
inhibited by aminoglycosides, oJ-CgTX, and dynorphine A 
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(1-13). In contrast, Cd 2÷ , La 3÷ and spider venom inhib- 
ited both the labeling of the 135 kDa band and non-specific 
labeling in the presence of unlabeled to-CgTX (Figs. 1, 
2A, 2B, 2C, 4 and 9A). Moreover, the concentration used 
for the Ca: + agonist and antagonists were almost he same 
in both the labeling and binding studies. 
(c) 125I-to-CgTX selectively labeled the 135 kDa band 
in the brain, but not in the other organs examined (Fig. 
10). This result was also consistent with that in 125I-to- 
CgTX binding (Fig. 5). Based on these similar findings, it 
seems likely that the 135 kDa band that is labeled with 
125I-to-CgTX by DSS in crude membranes from chick 
whole brain is closely related to the specific binding sites 
of lesI-to-CgTX, probably a/-subunits in neuronal VSCCs 
of the crude membranes, although it was reported that the 
Ca 2+ current of cloned N-type Ca 2+ channel al-subunit 
showed to-CgTX sensitivity by coexpression with fl-sub- 
unit but without a2-subunit, in mammalian HEK293 cells 
[36] or frog oocyte expression studies [37]. 
Further study is required to clarify the characteristics of 
the 135 kDa band in crude membranes from chick brain. 
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